Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment. The current treatment for glioblastoma multiform includes surgical removal of the tumor followed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisht, Priya, Kumar, V. Udaya, Pandey, Ruchi, Velayutham, Ravichandiran, Kumar, Nitesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297740/
https://www.ncbi.nlm.nih.gov/pubmed/35873570
http://dx.doi.org/10.3389/fphar.2022.939570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297740/
https://www.ncbi.nlm.nih.gov/pubmed/35873570
http://dx.doi.org/10.3389/fphar.2022.939570

Ejemplares similares